# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Serina Therapeutics, Inc. ("Serina") (NYSE:SER), a clinical-stage biotechnology company developing its proprietary POZ ...
Item 1.01 Entry into a Material Definitive Agreement On September 9, 2025, Serina Therapeutics, Inc., a Delaware corporation (t...
Transaction structured to provide flexible funding to support Phase 1b registrational clinical study program in advanced Parkin...
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Serina Therapeutics (AMEX:SER) with a Buy and maintains $15 pr...
SATS: 92% | EchoStar To Sell 3.45 GHz And 600 MHz Spectrum Licenses To AT&T For $23B, Establishes Hybrid MNO Agreement With...